Side-by-side · Research reference
DermorphinvsPTD-DBM
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED20/47 cited
BAnimal-StrongHUMAN-REVIEWED10/40 cited
Dermorphin
Opioid Peptide · μ-Receptor Agonist · Research Only
Research only · ICV / SC (animal models)
01Mechanism of Action
Parameter
Dermorphin
PTD-DBM
Primary target
μ-opioid receptors (central and peripheral)Negri 1992Steel 2014
CXXC5–Dishevelled protein-protein interaction
Pathway
μ-receptor activation → G-protein coupling → adenylyl cyclase inhibition → neuronal hyperpolarization
Downstream effect
Potent analgesia, reduced nociceptive signaling, opioid-mediated CNS and peripheral effects
Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation
Feedback intact?
N/A — exogenous opioid agonist
Not applicable — pathway derepression rather than receptor agonism
Origin
Phyllomedusa sauvagei and P. bicolor frog skin — gene-encoded with natural D-amino acid incorporationAmiche 1998Mignogna 1992
Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5
02Dosage Protocols
Parameter
Dermorphin
PTD-DBM
Legal status
Controlled substance in many jurisdictions · Research only
Not approved for human use.
—
Animal research (ICV)
Low nanomolar to picomolar range
Intracerebroventricular administration in rodent models.
—
Detection limit (doping)
5 pg/mL in equine plasma/urineSteel 2014
High-throughput LC-MS/MS screen developed for racing industry.
—
Duration of action
10–120 minutes (dose-dependent, intrathecal)
—
Evidence basis
Animal studies · In vitro assays
Animal models only (mice)
Human toxicity
Kambô ritual (P. bicolor skin) — violent emesis, vasodilation, fluid shifts, ADH dysregulationTran 2025
—
Wound healing protocol
—
Hydrogel patch delivery (concentration not disclosed)
Pyrogallol-HA patch, murine model.
Hair regeneration protocol
—
Topical application (exact dose not disclosed)
Wound-induced hair neogenesis model, mice.
Co-administration
—
Valproic acid (GSK-3β inhibitor) for wound healing synergyLee 2023
Combined treatment maximized scar reduction.
Human translation
—
No published human studies
04Side Effects & Safety
Parameter
Dermorphin
PTD-DBM
Opioid effects
Respiratory depression, sedation, euphoria, tolerance, dependence risk
—
Kambô ritual toxicity
Violent emesis, vasodilation, profound fluid shifts, hyponatremia, ADH dysregulation, brain death (case report)Tran 2025
—
Receptor selectivity caveat
Two μ-receptor subtypes — differential behavioral effects (analgesia vs. catalepsy)Negri 1992
—
Proteolytic stability
Tyr³-Pro⁶ bond relatively unstable; endogenous enzymes may produce tetrapeptide fragmentsCucumel 1996
—
Reported adverse events
—
None reported in animal studies
Wnt pathway activation risks
—
Theoretical risk of aberrant proliferation; Wnt dysregulation linked to tumorigenesis
Long-term safety
—
Unknown — no chronic dosing or human data
Delivery vehicle effects
—
HA-PG hydrogel well-tolerated in mice; human translation pending
Absolute Contraindications
Dermorphin
- ·Human use — not approved by any regulatory authority
- ·Controlled substance status — possession illegal in many jurisdictions
- ·Known opioid hypersensitivity or respiratory compromise
PTD-DBM
- ·Active malignancy (Wnt pathway involvement in tumorigenesis)
- ·Pregnancy / lactation (no safety data)
Relative Contraindications
Dermorphin
- ·Any context outside approved animal research protocols
- ·CNS depressant co-administration
PTD-DBM
- ·History of Wnt-driven tumors
- ·Skin lesions with uncertain malignant potential
05Administration Protocol
Parameter
Dermorphin
PTD-DBM
1. Legal and ethical framework
Dermorphin is a controlled substance in many jurisdictions and is not approved for human use. Possession, synthesis, or distribution may be illegal. Use is restricted to licensed research settings under institutional review.
Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days.Lee 2023
2. Animal research protocols
In rodent models, intracerebroventricular (ICV) or intrathecal injection is used at nanomolar to picomolar concentrations. Subcutaneous administration also documented. All protocols require IACUC approval.
Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models.Ryu 2023
3. Analytical detection
High-throughput LC-MS/MS screens developed for anti-doping programs detect dermorphin and 17 related peptides in equine and human urine/plasma at limits as low as 5 pg/mL.Steel 2014
PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream.Lee 2023
4. Kambô ritual (traditional use)
Application of Phyllomedusa bicolor skin secretions to superficial burns. Not recommended — associated with severe toxicity including violent emesis, hyponatremia, and documented case of brain death.Tran 2025
Not disclosed in available literature. Peptide stability and storage conditions not published.